In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.
|Articles|August 17, 2012
Doctors Play Key Role in ACO Leadership: Commonwealth Fund
Advertisement
Not many hospitals were participating or planning to participate in an accountable care organization last year, but among those that were, physicians were front and center in governance of the ACO, according to a
Read the full story:
Source: ModernHealthcare.com
The Commonwealth Fund reported that only about 13% of hospitals surveyed were participating or planning to participate in an ACO; 12% were unsure; and 75% said they were not exploring the model at all.
Advertisement
Related to this article
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Advertisement
Advertisement
Trending on AJMC
1
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
4
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
5